4.6 Review

Skull Base Tumors: Neuropathology and Clinical Implications

Journal

NEUROSURGERY
Volume 90, Issue 3, Pages 243-261

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1093/neuros/nyab209

Keywords

Skull base tumors; Neuropathology; Meningioma; Solitary fibrous tumor; Schwannoma; Adamantinomatous craniopharyngioma; Papillary craniopharyngioma; Pituitary adenoma; Pituicytoma; Granular cell tumor; Spindle cell oncocytoma; Pituitary blastoma; Chordoma chondrosarcoma; Langerhans cell histocytosis; Paraganglioma; Endolymphatic sac tumor

Ask authors/readers for more resources

Skull base tumors comprise a wide range of entities, with recent studies advancing understanding of their pathogenesis. Genotype plays a significant role in the phenotype of meningiomas, while Schwannomas are characterized by alterations in NF2 gene.
Tumors that arise in and around the skull base comprise a wide range of common and rare entities. Recent studies have advanced our understanding of their pathogenesis, which in some cases, have significantly influenced clinical practice. The genotype of meningiomas is strongly associated with their phenotype, including histologic subtype and tumor location, and clinical outcome. A single molecular alteration, NAB2-STAT6 fusion, has redefined the category of solitary fibrous tumors to include the previous entity hemangiopericytomas. Schwannomas, both sporadic and familial, are characterized by near ubiquitous alterations in NF2, with additional mutations in SMARCB1 or LZTR1 in schwannomatosis. In pituitary adenohypophyseal tumors, cell lineage transcription factors such as SF-1, T-PIT, and PIT-1 are now essential for classification, providing a more rigorous taxonomy for tumors that were previously considered null cell adenomas. The pituicyte lineage transcription factor TTF-1 defines neurohypophyseal tumors, which may represent a single nosological entity with a spectrum of morphologic manifestations (ie, granular cell tumor, pituicytoma, and spindle cell oncocytoma). Likewise, the notochord cell lineage transcription factor brachyury defines chordoma, discriminating them from chondrosarcomas. The identification of nonoverlapping genetic drivers of adamantinomatous craniopharyngiomas and papillary craniopharyngiomas indicates that these are distinct tumor entities and has led to successful targeted treatment of papillary craniopharyngiomas using BRAF and/or mitogen-activated protein kinase inhibitors. Similarly, dramatic therapeutic responses have been achieved in patients with Langerhans cell histiocytosis, both with BRAF-mutant and BRAF-wildtype tumors. Familiarity with the pathology of skull base tumors, their natural history, and molecular features is essential for optimizing patient care.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available